Personalized vaccine with or without toripalimab to prevent AML relapse
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a personalized cancer vaccine, alone or with an immunotherapy drug called toripalimab, to help keep acute myeloid leukemia (AML) in remission. It is for people who have finished initial treatment, are in remission, but still have some leukemia cells remaining (MRD positive) and have a specific NPM1 gene mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with acute myeloid leukemia (AML) and have completed induction and consolidation chemotherapy.
- You are currently in remission but have minimal (very small) amounts of leukemia still detectable.
- You have a specific NPM1 gene mutation (types A, D, G, H, B, or J).
- Your HLA type is HLA-A02:01 (a blood test will confirm this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests DC-AML immune cells to help people with acute myeloid leukemia (AML) who are in remission but still show signs of leftover cancer cells or relapse risk. It may help the immune system attack AML cells, especially when a stem cell transplant is not an option.
This trial tests a new type of maintenance therapy for acute myeloid leukemia (AML) patients who have already responded well to chemotherapy. The treatment uses your own immune cells to help prevent the cancer from coming back.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
This trial offers a personalized treatment plan for children with hard-to-treat or relapsed acute myeloid leukemia (AML). The plan is based on the unique genetic makeup of the child's cancer and lab tests that find the most effective drugs.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.